A DOUBLE-BLIND RANDOMIZED, PLACEBO-CONTROLLED STUDY AND OPEN-LABEL LONG TERM EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ELAFIBRANOR 80 MG IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS WITH INADEQUATE RESPONSE OR INTOLERANCE TO URSODEOXYCHOLIC ACID
- Registry ID
- GFT505B-319-1
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- IPSEN PHARMA SAS
- Start date
- 2022-03-03
- Last update
- 2020-12-21
Conditions
- NONALCOHOLIC STEATOHEPATITIS (NASH)
Related clinical trials
- A PHASE III DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL TO EVALUATE LIVER-RELATED CLINICAL OUTCOMES AND SAFETY OF ONCE WEEKLY INJECTED SURVODUTIDE IN PARTICIPANTS WITH COMPENSATED NON-ALCOHOLIC STEATOHEPATITIS/METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (NASH/MASH) CIRRHOSIS
- A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PHASE III TRIAL EVALUATING LONG-TERM EFFICACY AND SAFETY OF SURVODUTIDE WEEKLY INJECTIONS IN ADULT PARTICIPANTS WITH NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS/METABOLIC ASSOCIATED STEATOHEPATITIS (NASH/MASH) AND (F2) - (F3) STAGE OF LIVER FIBROSIS
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF EFRUXIFERMIN IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH)/METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING
THE SAFETY AND EFFICACY OF EFRUXIFERMIN IN SUBJECTS WITH NON-CIRRHOTIC
NONALCOHOLIC STEATOHEPATITIS (NASH)/METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND FIBROSIS (SYNCHRONY-HISTOLOGY)
- A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EFINOPEGDUTIDE (MK-6024) IN
ADULTS WITH PRECIRRHOTIC NONALCOHOLIC STEATOHEPATITIS
- A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFECT OF RESMETIROM ON LIVER-RELATED OUTCOMES IN PATIENTS WITH WELL-COMPENSATED (CHILD-PUGH A) NON-ALCOHOLIC STEATOHEPATITIS (NASH) CIRRHOSIS (MAESTRO-NASH OUTCOMES)
View on source registry